Anduhelm

Medicare has proposed limiting coverage of Aduhelm and several prominent groups representing patients and families are pressing to make it more widely available. But among individuals facing the disease, the outlook is more nuanced.

The condition can be an early signal of Alzheimer’s but not always. Other health concerns could be causing thinking or memory problems, and the new drug, Aduhelm, would not be appropriate for those patients.

The FDA approves new prescribing instructions for Aduhelm to address confusion over who should get the drug, saying it is appropriate for patients with early or mild Alzheimer’s.